2025
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatients
2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 35: 73-83. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-
2014
Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Xu H, Chen T, Wang W, Wu C, Liu C, Long J, Xu J, Zhang Y, Chen R, Liu L, Yu X. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. European Journal Of Nuclear Medicine And Molecular Imaging 2014, 41: 1093-1102. PMID: 24522797, DOI: 10.1007/s00259-014-2688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPancreatic NeoplasmsPositron-Emission TomographyPostoperative PeriodRadiopharmaceuticalsTomography, X-Ray ComputedTreatment OutcomeTumor BurdenConceptsSerum CA19-9 levelsRecurrence-free survivalMetabolic tumor volumeCA19-9 levelsMetabolic tumor burdenPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaTumor burdenOverall survivalTumor sizePancreatic ductal adenocarcinoma patientsSerum CA19-9Predicting overall survivalPancreatic cancer outcomesOperating characteristic analysisPredictive of outcomePET/CT examinationRadical pancreatectomyTumor volumeCA19-9Predicting OSSurrogate markerDuctal adenocarcinomaTLGMultivariate analysis
2003
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer.
Gonen M, Hummer A, Zervoudakis A, Sullivan D, Fong Y, Banerjee D, Klimstra D, Cordon-Cardo C, Bertino J, Kemeny N. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. Journal Of Clinical Oncology 2003, 21: 406-12. PMID: 12560427, DOI: 10.1200/jco.2003.06.060.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsDisease ProgressionDisease-Free SurvivalErbB ReceptorsFemaleGenetic MarkersHepatic ArteryHumansImmunohistochemistryInfusions, Intra-ArterialLiver NeoplasmsMaleMiddle AgedPredictive Value of TestsPrognosisThymidylate SynthaseTumor Suppressor Protein p53ConceptsHepatic progression-free survivalProgression-free survivalMetastatic colorectal cancerResectable metastatic colorectal cancerOverall survivalSystemic chemotherapyPredictors of survivalHepatic tumorsColorectal cancerResection marginsIncreased levels of serum alkaline phosphataseMultivariate analysisMarker expressionIndependent predictor of outcomeFactor of poor prognosisHepatic arterial infusionEpidermal growth factor receptorLevels of serum alkaline phosphatasePredicting overall survivalMultivariate Cox modelThymidylate synthase expressionPredictors of outcomeGrowth factor receptorSerum alkaline phosphataseLiver resection
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply